Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 2, 2016, Pages 198-207

  Vicini, P ^a,b,c   Fields, O ^a,b,c   Lai, E ^d   Litwack, E D ^g   Martin, A M ^f   Morgan, T M ^g   Pacanowski, M A ^e   Papaluca, M ^h   Perez, O D ^a,b,c   Ringel, M S ⁱ   Robson, M ^g   Sakul, H ^a,b,c   Vockley, J ^j   Zaks, T ^k   Dolsten, M ^a,b,c   Sogaard M ^a,b,c  

^a PFIZER INC   (United States)

^b Pfizer Global Research and Development   (United States)

^c Clinical Operations PfizerWorldwide Research and Development   (United States)

^d Takeda Pharmaceuticals International   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f GLAXOSMITHKLINE   (United States)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^h EUROPEAN MEDICINES AGENCY   (United Kingdom)

ⁱ BOSTON CONSULTING GROUP   (United States)

^j Inova Translational Medicine Institute   (United States)

^k SANOFI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; COPY NUMBER VARIATION; DNA SEQUENCE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MONITORING; GENE MUTATION; GENETIC ASSOCIATION; GENOMICS; GENOTYPE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; LARGE SCALE PRODUCTION; LARGE SCALE UNBIASED SEQUENCING; LAW; MEDICAL ETHICS; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SEQUENCE ALIGNMENT; TRANSCRIPTOMICS; WHOLE GENOME SEQUENCING; FACTUAL DATABASE; FOOD AND DRUG ADMINISTRATION; GENETIC SCREENING; LEGISLATION AND JURISPRUDENCE; PHARMACOGENETICS; STANDARDS; TRENDS; UNITED STATES;

DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; DRUG DISCOVERY; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PHARMACOGENETICS; PRECISION MEDICINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84956576960     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.293     Document Type: Review

References (75)

1. Hood, L. & Flores, M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. New Biotechnol. 29, 613-624 (2012).
2. President's Council of Advisors on Science and Technology. Priorities for Personalized Medicine. (2008).
3. Trusheim, M.R., Berndt, E.R. & Douglas, F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6, 287-293 (2007).
4. Momper, J.D. & Wagner, J.A. Therapeutic Drug Monitoring as a Component of Personalized Medicine: Applications in Pediatric Drug Development. Clin. Pharmacol. Ther. 95, 138-140 (2014).
5. Muller, P.Y. & Milton, M.N. The determination and interpretation of the therapeutic index in drug development. Nat. Rev. Drug Discov. 11, 751-761 (2012).
6. Walker, I. & Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8, 15-16 (2009).
7. Ramsey, B.W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011).
8. Dolsten, M. & Sogaard, M. Precision medicine: an approach to R&D for delivering superior medicines to patients. Clin. Transl. Med. 1, 7 (2012).
9. Scannell, J.W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200 (2012).
10. Modur, V., Hailman, E. & Barrett, J.C. Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics. Clin. Chem. 59, 102-109 (2013).
11. Mologni, L. Inhibitors of the anaplastic lymphoma kinase. Expert Opin. Investig. Drugs 21, 985-994 (2012).
12. Flaherty, K.T., Yasothan, U. & Kirkpatrick, P. Vemurafenib. Nat. Rev. Drug Discov. 10, 811-812 (2011).
13. Gazdar, A.F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N. Engl. J. Med. 361, 1018-1020 (2009).
14. O'Donnell, P.H. et al. The 1200 Patients Project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92, 446-449 (2012).
15. Pulley, J.M. et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT Project. Clin. Pharmacol. Ther. 92, 87-95 (2012).
16. Sims, D., Sudbery, I., Ilott, N.E., Heger, A. & Ponting, C.P. Sequencing depth and coverage: key considerations in genomic analyses. Nat. Rev. Genet. 15, 121-132 (2014).
17. The Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120 (2013).
18. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
19. Haga, S.B. 100k Genome Project: sequencing and much more. Personal. Med. 10, 761-764 (2013).
20. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421-427 (2014).
21. MacArthur, D.G. et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 335, 823-828 (2012).
22. Creighton, C.J., Reid, J.G. & Gunaratne, P.H. Expression profiling of microRNAs by deep sequencing. Brief. Bioinform. 10, 490-497 (2009).
23. Van Allen, E.M. et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat. Med. 20, 682-688 (2014).
24. Welch, J.S. et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305, 1577-1584 (2011).
25. Worthey, E.A. et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet. Med. 13, 255-262 (2011).
26. Bainbridge, M.N. et al. Whole-genome sequencing for optimized patient management. Sci. Transl. Med. 3, 87re3 (2011).
27. Choi, M. et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc. Natl. Acad. Sci. U. S. A. 106, 19096-19101 (2009).
28. Boisguerin, V. et al. Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside. Br. J. Cancer 111, 1469-1475 (2014).
29. Wilson, M.R. et al. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N. Engl. J. Med. 370, 2408-2417 (2014).
30. Saunders, C.J. et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci. Transl. Med. 4, 154ra135 (2012).
31. Kishnani, P.S. et al. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediatr. Res. 66, 329-335 (2009).
32. Lunshof, J.E. Whole genomes, small children, big questions. Personal. Med. 9, 667-669 (2012).
33. Dewey, F.E. et al. Clinical interpretation and implications of wholegenome sequencing. JAMA 311, 1035-1045 (2014).
34. Solomon, B.D. Obstacles and opportunities for the future of genomic medicine. Mol. Genet. Genomic Med. 2, 205-209 (2014).
35. Bodian, D.L. et al. Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. PLoS ONE 9, e94554 (2014).
36. Jorgenson, E. & Witte, J.S. A gene-centric approach to genome-wide association studies. Nat. Rev. Genet. 7, 885-891 (2006).
37. Badiee, A., Eiken, H., Steen, V. & Lovlie, R. Evaluation of five different cDNA labeling methods for microarrays using spike controls. BMC Biotechnol. 3, 23 (2003).
38. Lam, H.Y.K. et al. Performance comparison of whole-genome sequencing platforms. Nat. Biotech. 30, 78-82 (2012).
39. Zook, J.M. et al. Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat. Biotech. 32, 246-251 (2014).
40. Rehm, H.L. et al. ACMG clinical laboratory standards for nextgeneration sequencing. Genet. Med. 15, 733-747 (2013).
41. Gullapalli, R.R., Desai, K.V., Santana-Santos, L., Kant, J.A. & Becich, M.J. Next generation sequencing in clinical medicine: challenges and lessons for pathology and biomedical informatics. J. Pathol. Inform. 3, 40 (2012).
42. Miller, J.R., Koren, S. & Sutton, G. Assembly algorithms for nextgeneration sequencing data. Genomics 95, 315-327 (2010).
43. Ding, L., Wendl, M.C., McMichael, J.F. & Raphael, B.J. Expanding the computational toolbox for mining cancer genomes. Nat. Rev. Genet. 15, 556-570 (2014).
44. O'Rawe, J. et al. Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing. Genome Med. 5, 1-18 (2013).
45. Bodian, D.L. et al. Diagnosis of an imprinted-gene syndrome by a novel bioinformatics analysis of whole-genome sequences from a family trio. Mol. Genet. Genomic Med. 2, 530-538 (2014).
46. Biesecker, L.G. & Green, R.C. Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 370, 2418-2425 (2014).
47. Rosenfeld, J.A., Mason, C.E. & Smith, T.M. Limitations of the Human Reference Genome for personalized genomics. PLoS ONE 7, e40294 (2012).
48. Rehm, H.L. et al. ClinGen - the clinical genome resource. N. Engl. J. Med. 372, 2235-2242 (2015).
49. Evans, B.J., Burke, W. & Jarvik, G.P. The FDA and genomic tests - getting regulation right. N. Engl. J. Med. 372, 2258-2264 (2015).
50. Parkinson, D.R., Johnson, B.E. & Sledge, G.W. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin. Cancer Res. 18, 619-624 (2012).
51. European Parliament. Regulation (Ec) No 726/2004 of the European Parliament and of The Council of 31 March 2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. (2004).
52. Pignatti, F. et al. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European Union. Clin. Cancer Res. 20, 1458-1468 (2014).
53. Ehmann, F., Caneva, L. & Papaluca, M. European Medicines Agency initiatives and perspectives on pharmacogenomics. Br. J. Clin. Pharmacol. 77, 612-617 (2014).
54. European Medicines Agency. EMA scientific guidance documents on pharmacogenomics. (2015).
55. European Medicines Agency. Qualification of novel methodologies for medicine development. (2015).
56. Wolf, S.M. et al. Managing incidental findings in human subjects research: analysis and recommendations. J. Law Med. Ethics 36, 219-248 (2008).
57. Yang, Y. et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N. Engl. J. Med. 369, 1502-1511 (2013).
58. Burke, W. et al. Recommendations for returning genomic incidental findings? We need to talk! Genet. Med. 15, 854-859 (2013).
59. Knoppers, B.M., Joly, Y., Simard, J. & Durocher, F. The emergence of an ethical duty to disclose genetic research results: international perspectives. Eur. J. Hum. Genet. 14, 1170-1178 (2006).
60. Green, R.C. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15, 565-574 (2013).
61. Parkman, A. et al. Public awareness of genetic nondiscrimination laws in four states and perceived importance of life insurance protections. J. Genet. Counsel. 1-10 (2014).
62. European Medicines Agency. Reflection paper on pharmacogenomic samples, testing and data handling. (2007).
63. European Medicines Agency. Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products. (2015).
64. European Medicines Agency. Draft guideline on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products. (2015).
65. Liu, B. et al. Cloud-based bioinformatics workflow platform for largescale next-generation sequencing analyses. J. Biomed. Inform. 49, 119-133 (2014).
66. Rodrigues, J.J., de la Torre, I., Fernández, G. & López-Coronado, M. Analysis of the security and privacy requirements of cloud-based electronic health records systems. J. Med. Internet Res. 15, e186 (2013).
67. Trusheim, M.R. & Berndt, E.R. Economic challenges and possible policy actions to advance stratified medicine. Person. Med. 9, 413-427 (2012).
68. Chrystoja, C.C. & Diamandis, E.P. Whole genome sequencing as a diagnostic test: challenges and opportunities. Clin. Chem. 60, 724-733 (2014).
69. Trusheim, M.R. et al. Quantifying factors for the success of stratified medicine. Nat. Rev. Drug Discov. 10, 817-833 (2011).
70. Shashi, V. et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet. Med. 16, 176-182 (2014).
71. Desai, A.N. & Jere, A. Next-generation sequencing: ready for the clinics? Clin. Genet. 81, 503-510 (2012).
72. Lander, E.S. Cutting the Gordian helix - regulating genomic testing in the era of precision medicine. N. Engl. J. Med. 372, 1185-1186 (2015).
73. Kruglyak, K.M., Lin, E. & Ong, F.S. Next-generation sequencing in precision oncology: challenges and opportunities. Expert Rev. Mol. Diagn. 14, 635-637 (2014).
74. Brannon, A.R. & Sawyers, C.L. "N of 1" case reports in the era of whole-genome sequencing. J. Clin. Investig. 123, 4568-4570 (2013).
75. Feero, W. Clinical application of whole-genome sequencing: proceed with care. JAMA 311, 1017-1019 (2014).